Several other research firms have also recently weighed in on CTST. Citigroup initiated coverage on CannTrust in a report on Wednesday, July 3rd. They set a buy rating and a $7.00 price objective on the stock. Bloom Burton cut CannTrust from a buy rating to a hold rating in a report on Wednesday, July 10th. Eight Capital cut CannTrust from a buy rating to a neutral rating in a report on Monday, July 8th. Zacks Investment Research cut CannTrust from a buy rating to a hold rating in a report on Friday, August 9th. Finally, Bank of America cut CannTrust from a buy rating to an underperform rating and cut their price objective for the company from $9.00 to $4.50 in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. CannTrust presently has a consensus rating of Hold and a consensus price target of C$4.13.
Shares of NYSE:CTST traded down C$0.02 during trading on Wednesday, hitting C$1.09. 934,332 shares of the company’s stock traded hands, compared to its average volume of 2,707,124. CannTrust has a 52 week low of C$1.05 and a 52 week high of C$11.97. The company has a current ratio of 5.64, a quick ratio of 3.38 and a debt-to-equity ratio of 0.01. The company has a market cap of $157.04 million, a price-to-earnings ratio of -9.91 and a beta of 3.45. The company has a 50-day moving average price of C$1.58 and a 200-day moving average price of C$4.49.
CannTrust Holdings Inc produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc was incorporated in 2015 and is headquartered in Vaughan, Canada.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.